Welcome to our dedicated page for Personalis news (Ticker: PSNL), a resource for investors and traders seeking the latest updates and insights on Personalis stock.
Personalis, Inc. reports recurring developments in advanced genomics for precision oncology, with emphasis on personalized cancer testing, minimal residual disease monitoring and sequencing-based data analysis services. Company updates frequently center on the NeXT Personal ultrasensitive ctDNA assay, clinical test volume, clinical revenue, Medicare coverage for breast and lung cancer surveillance, and the shift toward commercial adoption of MRD testing.
News also covers clinical data presentations and publications in oncology settings, including breast, lung and colorectal cancer, as well as product features such as Real-Time Variant Tracker for therapy-resistance monitoring. Other recurring items include quarterly results, financial guidance, biopharma research applications and governance or management changes tied to the company’s precision oncology strategy.
Personalis, Inc. (NASDAQ: PSNL) announced a strategic partnership with the Moores Cancer Center at UC San Diego Health to enhance clinical diagnostic testing for patients with advanced tumors. This collaboration aims to utilize Personalis' advanced genomic tumor profiling test to inform FDA-approved therapy decisions and clinical trial options. The partnership also focuses on developing novel biomarkers and conducting research on a liquid biopsy assay that significantly improves sensitivity for detecting minimal residual disease and cancer recurrence, enhancing patient care.
Personalis, Inc. (NASDAQ: PSNL) announced that it will release its fourth quarter and full-year 2021 financial results on February 24, 2022. A conference call and webcast will follow at 2:00 p.m. PT / 5:00 p.m. ET to discuss these results and recent highlights. Interested parties can access the call via telephone or through the company's website. Personalis specializes in advanced cancer genomics, offering the Personalis NeXT Platform, which provides insights into approximately 20,000 human genes.
Personalis, Inc. (NASDAQ: PSNL), a leader in advanced cancer genomics, announced its management team will present at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 15, 2022, at 2:00 p.m. Eastern Time. The event will be accessible via a webcast link for attendees. Personalis is known for its Personalis NeXT Platform®, which provides comprehensive genomic information from tissue samples, facilitating precision cancer therapies and diagnostics. The lab is CLIA certified and CAP accredited, ensuring clinical accuracy and efficiency.
Personalis, Inc. (PSNL) announced preliminary revenue estimates for Q4 and the full year of 2021, reporting approximately $20.7 million for Q4 and $85.5 million for the full year. Revenue from biopharma customers reached $15.4 million in Q4 2021, reflecting a 102% increase year-over-year. However, revenue from the U.S. Department of Veterans Affairs Million Veterans Program fell 58% to $5.3 million in Q4 and decreased 19% for the year. The company holds an estimated $287 million in cash as of December 31, 2021.
Personalis, Inc. (NASDAQ: PSNL), a leader in cancer genomics, will present at the 24th Annual Needham Virtual Growth Conference on January 11, 2022. The company's innovative Personalis NeXT Platform® provides comprehensive genomic insights from tissue samples, aiding in precision oncology. Furthermore, Personalis is a key provider for Veterans Affairs' Million Veteran Program, reinforcing its position in population sequencing. The firm's lab emphasizes clinical accuracy with necessary certifications, ensuring top-tier service in advanced cancer diagnostics.
Personalis, Inc. (NASDAQ: PSNL) announced the launch of NeXT Personal, a next-generation tumor-informed liquid biopsy assay that enhances detection of molecular residual disease (MRD) with a sensitivity down to 1 part-per-million. This marks a 10- to 100-fold improvement over existing technologies, enabling earlier detection across various cancers, including challenging low mutational burden and early-stage cancers. NeXT Personal creates a tailored liquid biopsy panel from a patient’s tumor to better monitor cancer treatment.
Personalis, Inc. (NASDAQ: PSNL) announced participation in the 33rd Annual Piper Sandler Virtual Healthcare Conference on December 1, 2021. This event showcases Personalis' leadership in advanced cancer genomics aimed at precision cancer therapies. Interested parties can access a pre-recorded webcast of the presentation for 90 days through their website. Personalis’ NeXT Platform® supports comprehensive genomic insights from tissue samples, enhancing diagnostics for biopharmaceutical customers. For further details, visit investors.personalis.com.
Summary not available.
Personalis, a leader in advanced cancer genomics, will participate in the Society for Immunotherapy of Cancer Annual Meeting from November 12-14. The company will present online exhibits, including the Personalis NeXT Platform for comprehensive tumor and immune microenvironment analysis. Key presentations include research on liquid biopsies and therapeutic resistance in various cancers. An industry symposium titled 'Leveraging comprehensive genomic data for diagnostic capabilities' will also be featured on November 12.
Personalis, Inc. (Nasdaq: PSNL) reported a 12% increase in third-quarter revenue, totaling $22.3 million compared to $19.8 million in 2020. The company achieved record revenue of $8.6 million from biopharma clients, a 50% growth. New orders for cancer genomic testing exceeded quarterly revenue by three times. Notably, Personalis secured a $10 million contract with the VA Million Veteran Program. Despite these gains, the net loss rose to $17.7 million, worsening from a $9.5 million loss in the previous year. The fourth quarter outlook anticipates revenue between $20.2 million and $20.4 million.